Your Complete Monthly Cost Guide For Wegovy Treatment
BMI For Wegovy Requirements And Monthly Cost Planning
Wegovy is licensed for weight management in adults with a BMI of 30 or above, or those with a BMI of 27 or above who have at least one weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnoea. Understanding these BMI thresholds for Wegovy helps you determine eligibility, whilst our transparent monthly pricing structure allows you to budget effectively for long-term treatment. The MHRA-licensed indication ensures that Wegovy prescribing follows strict clinical criteria, making BMI assessment a crucial first step in your weight management journey.
Monthly costs for Wegovy vary depending on your current dose within the 16-week escalation schedule, starting at £79.99 for the 0.25mg starter dose and progressing to £209.99 monthly for the 2.4mg maintenance dose. This graduated pricing reflects the increasing strength required as your body adapts to semaglutide, with each dose carefully calibrated to minimise side effects whilst maximising weight management benefits. Planning your BMI assessment and monthly Wegovy costs together ensures you're prepared for the full treatment pathway, from initial prescription through to long-term maintenance therapy.
Wegovy Pricing Structure And Monthly Cost Breakdown
Our transparent pricing for BMI-eligible Wegovy patients begins with the 0.25mg starter dose at £79.99 monthly (weeks 1-4), progressing through 0.5mg at £94.99 (weeks 5-8), 1mg at £99.99 (weeks 9-12), and 1.7mg at £139.99 (weeks 13-16). The maintenance dose of 2.4mg, reached at week 17, costs £209.99 monthly and represents your ongoing treatment expense once dose escalation is complete. New customers benefit from discount code FIRST40 applied at checkout, whilst returning patients use code DOSE25 for continued savings on their Wegovy prescriptions.
Bundle options provide convenient supply planning for patients meeting BMI requirements for Wegovy, with our Intro Trio covering the first three doses (0.25mg, 0.5mg, and 1mg) for £299.99. The Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99, offering predictable costs for long-term treatment planning. These bundles ensure consistent supply without the need for monthly reordering, particularly valuable during the critical maintenance phase when BMI improvements are being sustained through continued Wegovy therapy.
Clinical Evidence For BMI-Based Wegovy Prescribing
The STEP clinical trial programme demonstrated significant weight management benefits for patients meeting BMI criteria for Wegovy treatment. In the landmark STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. These results validate the BMI-based prescribing criteria established by the MHRA for Wegovy therapy.
Long-term sustainability data from STEP 5 showed approximately clinically studied weight loss maintained at two years, whilst the recent SELECT trial demonstrated a 20% reduction in major cardiovascular events (HR 0.80). For patients meeting BMI requirements, Wegovy represents an evidence-based approach to weight management, with monthly costs justified by the substantial clinical benefits demonstrated across multiple large-scale trials.
How Wegovy Works For BMI-Eligible Patients
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone responsible for regulating appetite and food intake. Once injected weekly, semaglutide works on brain appetite centres to reduce hunger signals and promote feelings of fullness after smaller meals. This mechanism helps BMI-eligible patients achieve sustainable weight management by addressing the physiological drivers of overeating rather than relying solely on willpower. The medication may also reduce food cravings and slow gastric emptying, contributing to improved portion control. For patients meeting BMI criteria for Wegovy, this multifaceted approach provides pharmacological support for lifestyle modifications including reduced-calorie diet and increased physical activity.
Simple Ordering Process For BMI-Eligible Patients
Starting Wegovy treatment begins with our streamlined 3-minute online clinical assessment, which evaluates your BMI alongside other eligibility criteria such as previous weight management attempts and current health conditions. Our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), ensuring that your BMI and overall health profile make Wegovy appropriate for your circumstances. Once approved, your prescription is dispensed from our GPhC-registered pharmacy (#9012878) and delivered via next-day cold-chain transport to maintain the medication's integrity. This efficient process means BMI-eligible patients can begin their Wegovy journey quickly whilst ensuring all clinical safety requirements are met. Payment is processed securely with discount codes applied at checkout, providing transparent monthly costs from your very first order.
Storage And Practical Considerations For Monthly Wegovy Supply
Wegovy arrives in Novo Nordisk's FlexTouch pre-filled injection pens, requiring refrigeration at 2-8°C until first use, after which pens can be stored at room temperature below 30°C for up to 6 weeks. This storage flexibility makes monthly supply management convenient for most patients, whether maintaining treatment at home or travelling. Each pen contains four doses of your prescribed strength, administered once weekly via a simple subcutaneous injection that most patients find straightforward after initial training. The dose escalation schedule cannot be accelerated, ensuring your monthly costs follow the established progression from starter dose through to maintenance therapy. Proper storage and administration technique maximise the effectiveness of your monthly Wegovy investment whilst ensuring optimal weight management outcomes.
BMI Monitoring And Monthly Cost Optimisation During Treatment
Regular BMI tracking throughout Wegovy treatment helps demonstrate progress whilst optimising the value of your monthly investment. Most patients see gradual BMI reductions during the initial 16-week dose escalation period, with more significant changes typically evident once the 2.4mg maintenance dose is established. Monthly cost planning becomes more predictable at maintenance level, with the £209.99 monthly expense representing your ongoing investment in sustained weight management.
For returning customers, the DOSE25 discount code ensures continued savings on monthly Wegovy prescriptions, whilst bundle options like the Ultimate Stability Trio provide three-month supply security. Tracking BMI improvements alongside monthly costs helps patients appreciate the value delivered by Wegovy therapy, particularly when weight-related health conditions improve and long-term cardiovascular benefits become evident through sustained weight management success.
Start Your BMI-Based Wegovy Treatment Today
EverydayMeds makes starting Wegovy simple for BMI-eligible patients, with transparent monthly pricing, convenient online ordering, and expert clinical oversight from our qualified prescribers. New customers receive discount code FIRST40 applied at checkout, whilst returning patients benefit from DOSE25 for ongoing savings throughout their treatment journey. Our 3-minute clinical assessment evaluates your BMI and overall suitability for Wegovy, with next-day delivery ensuring prompt treatment initiation once approved. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and discover how our predictable monthly pricing supports your weight management goals. With GPhC registration (#9012878) guaranteeing genuine Novo Nordisk supply and expert pharmaceutical oversight, EverydayMeds provides the clinical excellence and cost transparency you deserve for BMI-based Wegovy treatment.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
